FDA Approval Withdrawal of Trodelvy Leaves Fewer Bladder Cancer Options
With the recent decision to rescind the Food and Drug Administration (FDA) approval of Trodelvy (sacituzumab govitecan-hziy) for the treatment of certain patients with bladder cancer, there is now one less treatment option available for patients and …